DR Corporation Limited (301177) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of DR Corporation Limited ¥5.26, price ¥23.37, upside -77.5%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch DR Corporation Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
57‑month range ¥16.82 – ¥146.74 · fair‑value band ¥4.10 – ¥6.84 · the ¥23.37 price screens above the ¥5.26 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow DR Corporation in your weekly email
Every Wednesday you see whether DR Corporation is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
DR Corporation Limited engages in the design and marketing of high-end engagement rings and fine jewelry worldwide. The company offers engagement rings, wedding rings, anniversary gifts, and bridal gold collections. It sells its products under the DR Diamond Ring brand through online and offline stores.
Show more
DR Corporation Limited engages in the design and marketing of high-end engagement rings and fine jewelry worldwide. The company offers engagement rings, wedding rings, anniversary gifts, and bridal gold collections. It sells its products under the DR Diamond Ring brand through online and offline stores. The company was founded in 2010 and is based in Shenzhen, China. DR Corporation Limited is a subsidiary of Shenzhen DR Investment Co., Ltd.
Stock analysis
DR Corporation Limited (301177) currently trades at ¥23.37, while our model-based Fair Value estimate is ¥5.26, implying the stock looks roughly 344.2% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ¥10.49 per share, and 0 of the 13 models we run sit above the ¥23.37 price.
Bear case: the Earnings-Based group reads lowest at ¥1.20, and 13 of the 13 models stay below the price. Evidence for this calculation is medium.
Scenario range: ¥4.10 (bear) to ¥6.84 (bull), the price of ¥23.37 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Consumer Cyclical sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
DR Corporation Limited reported revenue of 1.5B CNY in FY2025 versus 4.6B CNY in FY2021, a compound −24.3%/yr. Reported net income was 139M CNY in FY2025, compounding −42.8%/yr from FY2021.
Key figures
Market cap 10.6B CNY (≈ $1.6B) · P/E ratio 59.9 · P/S ratio 5.48 · EPS (TTM) ¥0.3900 · Dividend yield 2.1% · Net margin 9.2% · Return on equity 2.4% · Return on assets (EBIT) 5.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (medium confidence).
What moves the price
The share trades about 40% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Cyclical peers we cover trades at 9% fair-value upside, at −77%, 301177 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (¥1.20 to ¥10.49). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ¥4.10Fair Value ¥5.26Bull ¥6.84
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.19/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−25.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.2%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.5%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
−40.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−42.8%
Dividend (yield on the price)2.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.28% → 2%
2025 sits 102% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Luxury Goods · 134 stocks
Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score44 · Bottom 25%
Fair Value upside−78% · Bottom 25%
Profitability
Return on equity (TTM)2% · Below median
Return on assets0% · Bottom 25%
Net margin (TTM)11% · Top 25%
Operating margin (TTM)1% · Bottom 25%
Growth and dividend
Revenue growth−11% · Bottom 25%
Dividend yield (TTM)2.1% · Below median
Valuation Multiplesvs Luxury Goods median · lower = cheaper
P/E (TTM)59.9× · Priciest 25%
P/B1.69× · Cheaper than median
P/S (TTM)7.17× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)0· sector 49
PAST (return on equity)10· sector 40
HEALTH (low debt)0· sector 99
DIVIDEND (yield)43· sector 50
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is DR Corporation Limited (301177) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥5.26 versus a price of ¥23.37, about −77% upside (overvalued).
What is the fair value of 301177?
Our model-based fair value for DR Corporation Limited is ¥5.26 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥23.37.
What is the quality score of 301177?
DR Corporation Limited has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DR Corporation Limited (301177)?
Our model-based price target is the fair value of ¥5.26 (as of Sep 24, 2026) from 13 valuation models. Cautious scenario ¥4.10, optimistic scenario ¥6.84. It is a calculation from audited fundamentals, not an analyst target.
What is the DR Corporation Limited stock forecast for 2026?
Our models put fair value at ¥5.26, about −77% upside versus a price of ¥23.37 (overvalued). Cautious scenario ¥4.10, optimistic scenario ¥6.84. The calculation is refreshed regularly with new filings.
What is the revenue of DR Corporation Limited (301177)?
DR Corporation Limited reported trailing-twelve-month revenue of about 1.5B CNY (latest available figure, as of Sep 24, 2026).
Does DR Corporation Limited pay a dividend?
DR Corporation Limited currently shows a dividend yield of about 2.14% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of DR Corporation Limited (301177)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DR Corporation Limited it is ¥5.26 per share (as of Sep 24, 2026), against a price of ¥23.37. It is the blended result of 13 valuation models (cash flow, earnings, asset, dividend).
Is DR Corporation Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 301177 trades above its calculated fair value: price ¥23.37, fair value ¥5.26, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 301177?
No. The price is what the market pays today (¥23.37); the fair value is what the company's own numbers justify (¥5.26). For DR Corporation Limited the two are ¥18.11 per share apart. That gap is exactly why we show both numbers side by side.
How much is DR Corporation Limited worth?
The market values DR Corporation Limited at about 10.6B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥23.37; our models calculate a fair value of ¥5.26 per share.
What do the bullish and bearish scenarios say about 301177?
Our models span a range for DR Corporation Limited: cautious scenario ¥4.10, base ¥5.26, optimistic ¥6.84 per share (as of Sep 24, 2026, price ¥23.37). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 301177?
DR Corporation Limited trades at a price-to-earnings ratio of 59.9 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥5.26 is built from several models across several years. Other multiples: P/B 1.7, P/S 7.2.
How solid is the balance sheet of DR Corporation Limited (301177)?
Balance-sheet figures for DR Corporation Limited (as of Sep 24, 2026): return on equity 2.4%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 301177 from its 52-week high?
DR Corporation Limited trades at ¥23.37, about 40% below its 52-week high of ¥38.97 and 13% above the low of ¥20.62 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥5.26 is for.
Which stocks are comparable to DR Corporation Limited?
From the same area (Consumer Cyclical) we also value Compagnie Financière Richemont SA, Christian Dior SE, Kering SA, Tapestry, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DR Corporation Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ¥23.37, calculated fair value ¥5.26 (−77%), Quality Score 44/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 301177 calculated?
We run DR Corporation Limited through 13 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥5.26, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. DR Corporation Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DR Corporation Limited (301177)?
The closing price on Sep 22, 2026 was ¥23.37. Our model-based fair value is ¥5.26, about −77% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DR Corporation Limited right now?
The price sits above even our optimistic bull case (¥6.84). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts.
Key figures of DR Corporation Limited
How large is the market capitalisation of DR Corporation Limited (301177)?
The market capitalisation of DR Corporation Limited is 10.6B CNY (≈ $1.6B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DR Corporation Limited (301177)?
The price-to-sales ratio of DR Corporation Limited is 5.48 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DR Corporation Limited (301177)?
Earnings per share at DR Corporation Limited are ¥0.3900 (price ÷ EPS = P/E 59.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of DR Corporation Limited (301177)?
The dividend yield of DR Corporation Limited is 2.1% (payout 128%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DR Corporation Limited (301177)?
The net margin of DR Corporation Limited is 9.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DR Corporation Limited (301177)?
The return on equity (ROE) of DR Corporation Limited is 2.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DR Corporation Limited (301177)?
On an EBIT basis the return on assets of DR Corporation Limited is 5.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DR Corporation Limited (301177)?
The operating margin of DR Corporation Limited is 1.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DR Corporation Limited (301177)?
Revenue at DR Corporation Limited is growing −11.4% versus a year earlier (3y avg −25.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DR Corporation Limited (301177)?
Earnings per share at DR Corporation Limited are growing +80.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does DR Corporation Limited (301177) generate?
The free cash flow of DR Corporation Limited is −590M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does DR Corporation Limited (301177) carry?
The net debt of DR Corporation Limited is 535M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch DR Corporation Limited in the live analysis
One click puts DR Corporation Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
